413 related articles for article (PubMed ID: 19229701)
1. Somatic alterations of the serine/threonine kinase LKB1 gene in squamous cell (SCC) and large cell (LCC) lung carcinoma.
Strazisar M; Mlakar V; Rott T; Glavac D
Cancer Invest; 2009 May; 27(4):407-16. PubMed ID: 19229701
[TBL] [Abstract][Full Text] [Related]
2. ERBB2 kinase domain mutation in the lung squamous cell carcinoma.
Lee JW; Soung YH; Kim SY; Nam SW; Park WS; Wang YP; Jo KH; Moon SW; Song SY; Lee JY; Yoo NJ; Lee SH
Cancer Lett; 2006 Jun; 237(1):89-94. PubMed ID: 16029927
[TBL] [Abstract][Full Text] [Related]
3. Topoisomerase IIalpha gene expression is regulated by the p53 tumor suppressor gene in nonsmall cell lung carcinoma patients.
Liu D; Huang CL; Kameyama K; Hayashi E; Yamauchi A; Sumitomo S; Yokomise H
Cancer; 2002 Apr; 94(8):2239-47. PubMed ID: 12001123
[TBL] [Abstract][Full Text] [Related]
4. LKB1 mutation in large cell carcinoma of the lung.
Zhong D; Guo L; de Aguirre I; Liu X; Lamb N; Sun SY; Gal AA; Vertino PM; Zhou W
Lung Cancer; 2006 Sep; 53(3):285-94. PubMed ID: 16822578
[TBL] [Abstract][Full Text] [Related]
5. LKB1 gene mutations in Japanese lung cancer patients.
Onozato R; Kosaka T; Achiwa H; Kuwano H; Takahashi T; Yatabe Y; Mitsudomi T
Cancer Sci; 2007 Nov; 98(11):1747-51. PubMed ID: 17711506
[TBL] [Abstract][Full Text] [Related]
6. Abnormalities of epidermal growth factor receptor in lung squamous-cell carcinomas, adenosquamous carcinomas, and large-cell carcinomas: tyrosine kinase domain mutations are not rare in tumors with an adenocarcinoma component.
Ohtsuka K; Ohnishi H; Fujiwara M; Kishino T; Matsushima S; Furuyashiki G; Takei H; Koshiishi Y; Goya T; Watanabe T
Cancer; 2007 Feb; 109(4):741-50. PubMed ID: 17238183
[TBL] [Abstract][Full Text] [Related]
7. Mutations of K-ras oncogene and absence of H-ras mutations in squamous cell carcinomas of the lung.
Vachtenheim J; Horáková I; Novotná H; Opáalka P; Roubková H
Clin Cancer Res; 1995 Mar; 1(3):359-65. PubMed ID: 9815992
[TBL] [Abstract][Full Text] [Related]
8. Reduced transcription of the RB2/p130 gene in human lung cancer.
Xue Jun H; Gemma A; Hosoya Y; Matsuda K; Nara M; Hosomi Y; Okano T; Kurimoto F; Seike M; Takenaka K; Yoshimura A; Toyota M; Kudoh S
Mol Carcinog; 2003 Nov; 38(3):124-9. PubMed ID: 14587097
[TBL] [Abstract][Full Text] [Related]
9. Alterations in novel candidate tumor suppressor genes, ING1 and ING2 in human lung cancer.
Okano T; Gemma A; Hosoya Y; Hosomi Y; Nara M; Kokubo Y; Yoshimura A; Shibuya M; Nagashima M; Harris CC; Kudoh S
Oncol Rep; 2006 Mar; 15(3):545-9. PubMed ID: 16465410
[TBL] [Abstract][Full Text] [Related]
10. Detection by denaturant gradient gel electrophoresis of tumor-specific mutations in biopsies and relative bronchoalveolar lavage fluid from resectable non-small cell lung cancer.
Ferretti G; Curigliano G; Pastorino U; Cittadini A; Flamini G; Calabrò MG; De Pas T; Orlando L; Mandalà M; Colleoni M; Spaggiari L; Granone PL; Pagliari G; de Braud F; Fazio N; Goldhirsch A
Clin Cancer Res; 2000 Jun; 6(6):2393-400. PubMed ID: 10873091
[TBL] [Abstract][Full Text] [Related]
11. Somatic mutations of the protein kinase gene family in human lung cancer.
Davies H; Hunter C; Smith R; Stephens P; Greenman C; Bignell G; Teague J; Butler A; Edkins S; Stevens C; Parker A; O'Meara S; Avis T; Barthorpe S; Brackenbury L; Buck G; Clements J; Cole J; Dicks E; Edwards K; Forbes S; Gorton M; Gray K; Halliday K; Harrison R; Hills K; Hinton J; Jones D; Kosmidou V; Laman R; Lugg R; Menzies A; Perry J; Petty R; Raine K; Shepherd R; Small A; Solomon H; Stephens Y; Tofts C; Varian J; Webb A; West S; Widaa S; Yates A; Brasseur F; Cooper CS; Flanagan AM; Green A; Knowles M; Leung SY; Looijenga LH; Malkowicz B; Pierotti MA; Teh BT; Yuen ST; Lakhani SR; Easton DF; Weber BL; Goldstraw P; Nicholson AG; Wooster R; Stratton MR; Futreal PA
Cancer Res; 2005 Sep; 65(17):7591-5. PubMed ID: 16140923
[TBL] [Abstract][Full Text] [Related]
12. High-grade neuroendocrine carcinoma of the lung shows increased thymidylate synthase expression compared to other histotypes.
Ibe T; Shimizu K; Nakano T; Kakegawa S; Kamiyoshihara M; Nakajima T; Kaira K; Takeyoshi I
J Surg Oncol; 2010 Jul; 102(1):11-7. PubMed ID: 20578072
[TBL] [Abstract][Full Text] [Related]
13. Association of O6-methylguanine-DNA methyltransferase (MGMT) promoter methylation with p53 mutation occurrence in non-small cell lung cancer with different histology, gender, and smoking status.
Wu JY; Wang J; Lai JC; Cheng YW; Yeh KT; Wu TC; Chen CY; Lee H
Ann Surg Oncol; 2008 Nov; 15(11):3272-7. PubMed ID: 18712569
[TBL] [Abstract][Full Text] [Related]
14. Distinctive gene expression of human lung adenocarcinomas carrying LKB1 mutations.
Fernandez P; Carretero J; Medina PP; Jimenez AI; Rodriguez-Perales S; Paz MF; Cigudosa JC; Esteller M; Lombardia L; Morente M; Sanchez-Verde L; Sotelo T; Sanchez-Cespedes M
Oncogene; 2004 Jun; 23(29):5084-91. PubMed ID: 15077168
[TBL] [Abstract][Full Text] [Related]
15. Frequent polymorphic variations but rare tumour specific mutations of the S100A2 on 1q21 in non-small cell lung cancer.
Strazisar M; Rott T; Glavac D
Lung Cancer; 2009 Mar; 63(3):354-9. PubMed ID: 18656279
[TBL] [Abstract][Full Text] [Related]
16. The 3' UTR IGF2R-A2/B2 variant is associated with increased tumor growth and advanced stages in non-small cell lung cancer.
Kotsinas A; Evangelou K; Sideridou M; Kotzamanis G; Constantinides C; Zavras AI; Douglass CW; Papavassiliou AG; Gorgoulis VG
Cancer Lett; 2008 Feb; 259(2):177-85. PubMed ID: 18037232
[TBL] [Abstract][Full Text] [Related]
17. Inactivation of LKB1/STK11 is a common event in adenocarcinomas of the lung.
Sanchez-Cespedes M; Parrella P; Esteller M; Nomoto S; Trink B; Engles JM; Westra WH; Herman JG; Sidransky D
Cancer Res; 2002 Jul; 62(13):3659-62. PubMed ID: 12097271
[TBL] [Abstract][Full Text] [Related]
18. k-ras mutation and occupational asbestos exposure in lung adenocarcinoma: asbestos-related cancer without asbestosis.
Nelson HH; Christiani DC; Wiencke JK; Mark EJ; Wain JC; Kelsey KT
Cancer Res; 1999 Sep; 59(18):4570-3. PubMed ID: 10493509
[TBL] [Abstract][Full Text] [Related]
19. Defective expression of transforming growth factor beta type II receptor (TGFBR2) in the large cell variant of non-small cell lung carcinoma.
Xu JB; Bao Y; Liu X; Liu Y; Huang S; Wang JC
Lung Cancer; 2007 Oct; 58(1):36-43. PubMed ID: 17566598
[TBL] [Abstract][Full Text] [Related]
20. Effect of the p53 codon 72 and intron 3 polymorphisms on non-small cell lung cancer (NSCLC) prognosis.
Boldrini L; Gisfredi S; Ursino S; Lucchi M; Greco G; Mussi A; Donati V; Fontanini G
Cancer Invest; 2008 Mar; 26(2):168-72. PubMed ID: 18259947
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
